ArticleResearch in pharmaceutical sciences2026
Association of fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acyl-coenzyme A synthetase long-chain 4 (ACSL4) expression and human epidermal growth factor receptor 2 (HER2) status with metastasis and survival in breast cancer: a five-year follow-up.
Article in Research in pharmaceutical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Breast cancer is one of the leading causes of death among women worldwide, with rising incidence rates, particularly in rapidly developing countries such as Iran. This study aimed to investigate the relationship between lipid metabolism enzymes, fatty acid synthase (FASN), ATP-citrate lyase (ACLY), and acyl-CoA synthetase long-chain family member 4 (ACSL4), and patient survival, with a focus on their potential role in breast cancer metastasis. In addition, we evaluated the prognostic significance of human epidermal growth factor receptor 2 (HER-2) overexpression in breast cancer patients. Experimental approach: A total of 52 breast cancer tissue samples were collected from patients at Ordibehesht Clinic in Isfahan, Iran. RNA was extracted and analyzed using qRT-PCR to quantify the expression of FASN, ACLY, and ACSL4. Kaplan-Meier survival curves and log-rank tests were applied to assess survival rates and metastasis. Findings/Results: The Kaplan-Meier analysis showed an average time to metastasis of 36.18 months. No significant associations were found between metastasis and the expression levels of ACLY, FASN, or ACSL4. In contrast, HER-2 expression was significantly associated with metastasis, underscoring its potential as a critical prognostic marker. Other clinicopathological factors, including tumor grade, stage, size, and receptor status, were not significantly related to metastasis. Conclusion and implications: Our study highlights the importance of HER-2 as a key prognostic marker in breast cancer and suggests that further research is required to clarify the mechanisms underlying its role in cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.